Chronic acid-related disorders are common and underinvestigated
- PMID: 14638341
- DOI: 10.1111/j.1572-0241.2003.07706.x
Chronic acid-related disorders are common and underinvestigated
Abstract
Objectives: The aims of this study were as follows: to establish the prevalence of chronic acid-related disorders in a managed care population; to describe these patients; and to examine rates of adherence to current guidelines for investigation of dyspepsia and peptic ulcer disease.
Methods: The design was a population-based cohort study. The sample was drawn from 216,720 adult (aged >18 yr) members of a managed care organization that had an electronic medical record linked to administrative and pharmacy databases. We included adults with continuous enrollment from July, 1998, to January, 2000, who were dispensed histamine-2 blockers or proton-pump inhibitors, or both, for > or =1 yr. Dispensing data, sociodemographic and clinical information, comorbidities, and investigations were collected and analyzed.
Results: The final cohort consisted of 5064 patients; 64% were aged > or =50 yr, 47% were male, and 11% were African American. The prevalence of chronic acid-related disorders was 2.3%. Gastroesophageal reflux disease (59%) was the most common condition, followed by dyspepsia (35% of cohort; 18% investigated by endoscopy). There were 917 dyspepsia patients > or =50 yr who had not been investigated by endoscopy (81% of dyspepsia patients in this age group). There were 97 patients with peptic ulcer disease who did not have a documented test for Helicobacter pylori (34% of patients with peptic ulcer disease).
Conclusions: Chronic acid-related disorders are common in primary care, and many patients use acid suppressing medications on a long-term basis. Nevertheless, according to current practice guidelines, our patients were underinvestigated. Future guidelines should specifically address the management of patients who use acid suppressing medications on a chronic basis.
Similar articles
-
The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia.Am J Gastroenterol. 2003 Sep;98(9):1952-62. doi: 10.1111/j.1572-0241.2003.07584.x. Am J Gastroenterol. 2003. PMID: 14499771
-
A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease.Arch Intern Med. 2003 May 26;163(10):1165-71. doi: 10.1001/archinte.163.10.1165. Arch Intern Med. 2003. PMID: 12767952 Clinical Trial.
-
Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.CMAJ. 2000 Mar 21;162(6):817-23. CMAJ. 2000. PMID: 10750472 Free PMC article.
-
[25 years of gastric acid blockers].Ned Tijdschr Geneeskd. 1999 Dec 11;143(50):2501-4. Ned Tijdschr Geneeskd. 1999. PMID: 10627749 Review. Dutch.
-
Dyspepsia and Helicobacter pylori.Dig Dis. 2008;26(3):210-4. doi: 10.1159/000121348. Epub 2008 May 6. Dig Dis. 2008. PMID: 18463437 Review.
Cited by
-
Dyspepsia and its overlap with irritable bowel syndrome.Curr Gastroenterol Rep. 2006 Aug;8(4):266-72. doi: 10.1007/s11894-006-0046-0. Curr Gastroenterol Rep. 2006. PMID: 16888867 Review.
-
Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders.Clin Transl Gastroenterol. 2024 Nov 1;15(11):e00776. doi: 10.14309/ctg.0000000000000776. Clin Transl Gastroenterol. 2024. PMID: 39412166 Free PMC article.
-
Overtesting and undertesting in primary care: a systematic review and meta-analysis.BMJ Open. 2018 Feb 11;8(2):e018557. doi: 10.1136/bmjopen-2017-018557. BMJ Open. 2018. PMID: 29440142 Free PMC article.
-
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Clin Pharmacol. 2013 Apr 16;5:59-66. doi: 10.2147/CPAA.S41999. Print 2013. Clin Pharmacol. 2013. PMID: 23637566 Free PMC article.
-
Antiulcer drugs and gastric cancer.Dig Dis Sci. 2005 Oct;50 Suppl 1:S39-44. doi: 10.1007/s10620-005-2805-4. Dig Dis Sci. 2005. PMID: 16184420 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical